LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

UroGen Pharma Ltd

Suletud

13.41 2.44

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.99

Max

13.73

Põhinäitajad

By Trading Economics

Sissetulek

-6.3M

-44M

Müük

-4.3M

20M

Aktsiakasum

-0.92

Kasumimarginaal

-216.466

Töötajad

234

EBITDA

-6.2M

-37M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+143.66% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. aug 2025

Turustatistika

By TradingEconomics

Turukapital

167M

686M

Eelmine avamishind

10.97

Eelmine sulgemishind

13.41

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

UroGen Pharma Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. juuni 2025, 18:34 UTC

Suurimad hinnamuutused turgudel

UroGen Pharma Shares Rise on FDA Approval of Bladder Cancer Drug

16. mai 2025, 19:39 UTC

Suurimad hinnamuutused turgudel

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

Võrdlus sarnastega

Hinnamuutus

UroGen Pharma Ltd Prognoos

Hinnasiht

By TipRanks

143.66% tõus

12 kuu keskmine prognoos

Keskmine 33.43 USD  143.66%

Kõrge 50 USD

Madal 16 USD

Põhineb 7 Wall Streeti analüütiku instrumendi UroGen Pharma Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

6

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

9.625 / 11.64Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.